Business Insider

Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society ...

NEW HAVEN, Conn., June 28, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is presenting expanded data from two randomized, pivotal Phase 3 clinical trials of rimegepant ...
Business Insider

Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting ...

NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced it will present 16 scientific presentations (oral and poster) highlighting ...
Healio

Rimegepant superior to placebo in patients with migraine unresponsive to triptans

Please provide your email address to receive an email when new articles are posted on . Rimegepant offered superior sustained pain relief, pain freedom and normal function up to 48 hours. Most adverse ...
Nasdaq

Biohaven, Pfizer Get Positive CHMP Opinion For Rimegepant To Treat Migraine

(RTTNews) - Biohaven Pharmaceutical Holding Company Ltd. (BHVN), and Pfizer Inc. (PFE), said on Friday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency ...
Nasdaq

Biohaven Pharma: Rimegepant Asia-Pacific Phase 3 Study Meets Co-primary Endpoints

(RTTNews) - Biohaven Pharmaceutical Holding Company Ltd. (BHVN) and Pfizer Inc. (PFE) reported positive top-line results from an Asia-Pacific, phase 3 clinical trial of rimegepant in adults for the ...